PRN: Beta-Secretase (BACE) Inhibitors Pipeline Analysis, 2017 - 15 Product Candidates in Different Stages of Development

02/ago/2017 13:31:06 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Beta-Secretase (BACE) Inhibitors Pipeline Analysis, 2017 - 15 Product Candidates in Different Stages of Development


DUBLIN, August 2, 2017 /PRNewswire/ --

The "Beta-Secretase (BACE) Inhibitors Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments" report has been added to Research and Markets' offering.

Research and Markets Logo

BACE is a cleaving enzyme of aspartyl protease with beta-secretase activity. It acts as a precursor of beta-amyloid (Aß) protein. In Alzheimer's disease, the Aß protein fragments get accumulated in plaques in the brain. BACE initiates Aß production by cleaving amyloid precursor protein (APP) to generate APPß and C99, which is critical for the subsequent cleavage of C99 by gamma-secretase to release Aß1-40 and Aß1-42. Inhibition of BACE enzyme disrupts the production of toxic Aß and forms plaque and new soluble oligomers.

Alzheimer's disease is a common type of dementia and a fatal illness. It includes memory loss and loss of other intellectual abilities, which results in serious interference with daily life. Around 60% to 80% of dementia cases turn out to be Alzheimer's disease. It causes problems with behavior, thinking and memory. Symptoms usually develop at a slow rate and become worse with time, causing severe interference with daily routine. The efficient inhibition of BACE is expected to stop the progression of Alzheimer's disease. BACE inhibitors as drug candidates will block Aß enzyme, which would prevent the buildup of beta-amyloid and may also help to reduce or halt Alzheimer's disease.

Although significant progress has been witnessed in BACE inhibitor development, studies are still focused on BACE inhibitors with high potential, and reduced or no side effects. Also, even after promising growth in the development of BACE inhibitors, BACE therapeutics for Alzheimer's disease treatment are still not available in the market due to the difficulty in the designing of BACE1 inhibitor drugs that can pass the blood-brain barrier.

As of February 2017, the BACE inhibitors pipeline comprised 15 product candidates in different stages of development.

Key Topics Covered:

1. Research Background

2. Research Methodology

3. Executive Summary

4. Pipeline Outlook

5. Beta-Secretase (Bace) Inhibitors Pipeline Analysis By Phase (2017)

6 Competitive Landscape

7 Company Profiles

8 Appendix

For more information about this report visit !

Media Contact:

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


blog comments powered by Disqus è un servizio offerto da Factotum Srl